# LifeMD, Inc.: financial statements, quarterly

LFMD · Nasdaq · CIK 948320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lfmd.md) · [Financials](/companies/lfmd/financials.md) · [Filings](/companies/lfmd/filings.md) · [Insiders](/companies/lfmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lfmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [38.6](/filings/0001493152-24-044032.md) | [44.9 d](/filings/0001493152-25-009790.md) | [44.1](/filings/0001641172-25-008864.md) | [50.7](/filings/0001641172-25-022272.md) | [53.3](/filings/0001493152-25-023906.md) | [5.5 d](/filings/0001493152-26-009549.md) | [50.9](/filings/0001493152-26-021536.md) | [49.0](/filings/0001493152-26-036200.md) | [60.2](/filings/0001493152-25-023906.md) | [7.1 d](/filings/0001493152-26-009549.md) | [50.2](/filings/0001493152-26-021536.md) | [47.3](/filings/0001493152-26-036200.md) |
| Cost of revenue | $m | [4.8](/filings/0001493152-24-044032.md) | [5.4 d](/filings/0001493152-25-009790.md) | [4.6](/filings/0001641172-25-008864.md) | [5.0](/filings/0001641172-25-022272.md) | [5.0](/filings/0001493152-25-023906.md) | [6.8 d](/filings/0001493152-26-009549.md) | [8.1](/filings/0001493152-26-021536.md) | [6.8](/filings/0001493152-26-036200.md) | [7.4](/filings/0001493152-25-023906.md) | [4.2 d](/filings/0001493152-26-009549.md) | [5.9](/filings/0001493152-26-021536.md) | [5.3](/filings/0001493152-26-036200.md) |
| Gross profit | $m | [33.8](/filings/0001493152-24-044032.md) | [39.5 d](/filings/0001493152-25-009790.md) | [39.5](/filings/0001641172-25-008864.md) | [45.6](/filings/0001641172-25-022272.md) | [48.3](/filings/0001493152-25-023906.md) | [(1.3) d](/filings/0001493152-26-009549.md) | [42.8](/filings/0001493152-26-021536.md) | [42.2](/filings/0001493152-26-036200.md) | [52.8](/filings/0001493152-25-023906.md) | [2.8 d](/filings/0001493152-26-009549.md) | [44.2](/filings/0001493152-26-021536.md) | [42.0](/filings/0001493152-26-036200.md) |
| Operating income | $m | [(4.6)](/filings/0001493152-24-044032.md) | [(2.2) d](/filings/0001493152-25-009790.md) | [(6.2)](/filings/0001641172-25-008864.md) | [(6.3)](/filings/0001641172-25-022272.md) | [(4.0)](/filings/0001493152-25-023906.md) | [(6.0) d](/filings/0001493152-26-009549.md) | [(1.2)](/filings/0001493152-26-021536.md) | [(2.3)](/filings/0001493152-26-036200.md) | [(2.0)](/filings/0001493152-25-023906.md) | [(6.2) d](/filings/0001493152-26-009549.md) | [(8.9)](/filings/0001493152-26-021536.md) | [(7.1)](/filings/0001493152-26-036200.md) |
| Interest expense | $m | [0.7](/filings/0001493152-24-044032.md) | [0.6 d](/filings/0001493152-25-009790.md) | [0.5](/filings/0001641172-25-008864.md) | [0.5](/filings/0001641172-25-022272.md) | [0.6](/filings/0001493152-25-023906.md) | [0.6 d](/filings/0001493152-26-009549.md) | [0.5](/filings/0001493152-26-021536.md) | [0.7](/filings/0001493152-26-036200.md) | [0.3](/filings/0001493152-25-023906.md) | [(0.2) d](/filings/0001493152-26-009549.md) | [(0.1)](/filings/0001493152-26-021536.md) | [(0.0)](/filings/0001493152-26-036200.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | [0.2](/filings/0001493152-25-023906.md) | [0.4 d](/filings/0001493152-26-009549.md) | not reported | not reported | [0.2](/filings/0001493152-25-023906.md) | [(0.1) d](/filings/0001493152-26-009549.md) | not reported | not reported |
| Net income | $m | [(6.1)](/filings/0001493152-24-044032.md) | [(3.7) d](/filings/0001493152-25-009790.md) | [(6.8)](/filings/0001641172-25-008864.md) | [(6.9)](/filings/0001641172-25-022272.md) | [(4.7)](/filings/0001493152-25-023906.md) | [(4.9) d](/filings/0001493152-26-009549.md) | [(0.2)](/filings/0001493152-26-021536.md) | [(1.6)](/filings/0001493152-26-036200.md) | [(3.8)](/filings/0001493152-25-023906.md) | [20.0 d](/filings/0001493152-26-009549.md) | [(8.9)](/filings/0001493152-26-021536.md) | [(7.1)](/filings/0001493152-26-036200.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | [(0.13)](/filings/0001493152-25-023906.md) | not reported | [(0.02)](/filings/0001493152-26-021536.md) | [(0.05)](/filings/0001493152-26-036200.md) | not reported | not reported | [(0.20)](/filings/0001493152-26-021536.md) | [(0.16)](/filings/0001493152-26-036200.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | [(0.13)](/filings/0001493152-25-023906.md) | not reported | [(0.02)](/filings/0001493152-26-021536.md) | [(0.05)](/filings/0001493152-26-036200.md) | not reported | not reported | [(0.20)](/filings/0001493152-26-021536.md) | [(0.16)](/filings/0001493152-26-036200.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2024-03-31) | period not labelled (2024-05-08) | Q2 FY2024 (2024-06-30) | period not labelled (2024-08-07) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [35.1](/filings/0001493152-24-018250.md) | [29.3](/filings/0001493152-24-018250.md) | [35.7](/filings/0001493152-24-030564.md) | [32.6](/filings/0001493152-24-044032.md) | [37.6](/filings/0001493152-24-044032.md) | [35.0](/filings/0001641172-25-022272.md) | [34.4](/filings/0001641172-25-008864.md) | [36.2](/filings/0001641172-25-022272.md) | [23.8](/filings/0001493152-25-023906.md) | [36.8](/filings/0001493152-26-036200.md) | [34.5](/filings/0001493152-26-021536.md) | [25.1](/filings/0001493152-26-036200.md) |
| Current assets | $m | [44.4](/filings/0001493152-24-018250.md) | not reported | [45.1](/filings/0001493152-24-030564.md) | not reported | [48.7](/filings/0001493152-24-044032.md) | [52.4](/filings/0001493152-26-009549.md) | [50.0](/filings/0001641172-25-008864.md) | [49.0](/filings/0001641172-25-022272.md) | [41.1](/filings/0001493152-25-023906.md) | [51.8](/filings/0001493152-26-036200.md) | [51.7](/filings/0001493152-26-021536.md) | [42.1](/filings/0001493152-26-036200.md) |
| Total assets | $m | [61.5](/filings/0001493152-24-018250.md) | not reported | [63.8](/filings/0001493152-24-030564.md) | not reported | [72.6](/filings/0001493152-24-044032.md) | [76.1](/filings/0001493152-26-009549.md) | [73.6](/filings/0001641172-25-008864.md) | [73.6](/filings/0001641172-25-022272.md) | [66.0](/filings/0001493152-25-023906.md) | [70.4](/filings/0001493152-26-036200.md) | [70.1](/filings/0001493152-26-021536.md) | [59.9](/filings/0001493152-26-036200.md) |
| Current liabilities | $m | [44.7](/filings/0001493152-24-018250.md) | not reported | [51.6](/filings/0001493152-24-030564.md) | not reported | [59.0](/filings/0001493152-24-044032.md) | [67.4](/filings/0001493152-26-009549.md) | [60.9](/filings/0001641172-25-008864.md) | [63.5](/filings/0001641172-25-022272.md) | [56.7](/filings/0001493152-25-023906.md) | [41.6](/filings/0001493152-26-036200.md) | [49.6](/filings/0001493152-26-021536.md) | [46.6](/filings/0001493152-26-036200.md) |
| Total liabilities | $m | [60.2](/filings/0001493152-24-018250.md) | not reported | [65.9](/filings/0001493152-24-030564.md) | not reported | [78.5](/filings/0001493152-24-044032.md) | [83.7](/filings/0001493152-26-009549.md) | [74.0](/filings/0001641172-25-008864.md) | [73.2](/filings/0001641172-25-022272.md) | [62.6](/filings/0001493152-25-023906.md) | [47.3](/filings/0001493152-26-036200.md) | [55.1](/filings/0001493152-26-021536.md) | [51.9](/filings/0001493152-26-036200.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [15.9](/filings/0001641172-25-022272.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(0.8)](/filings/0001493152-24-018250.md) | not reported | [(4.2)](/filings/0001493152-24-030564.md) | not reported | [(7.7)](/filings/0001493152-24-044032.md) | [(9.1)](/filings/0001493152-26-009549.md) | [(2.3)](/filings/0001641172-25-008864.md) | [(1.8)](/filings/0001641172-25-022272.md) | [1.3](/filings/0001493152-25-023906.md) | [23.2](/filings/0001493152-26-036200.md) | [15.0](/filings/0001493152-26-021536.md) | [8.0](/filings/0001493152-26-036200.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,076 d](/filings/0001493152-24-044032.md) | [5,714 d](/filings/0001493152-25-009790.md) | [5,202](/filings/0001641172-25-008864.md) | [4,540 d](/filings/0001641172-25-022272.md) | [6,698 d](/filings/0001493152-25-023906.md) | [1,073 d](/filings/0001493152-26-009549.md) | [3,068](/filings/0001493152-26-021536.md) | [8,639 d](/filings/0001493152-26-036200.md) | [(147) d](/filings/0001493152-25-023906.md) | [(3,281) d](/filings/0001493152-26-009549.md) | [445](/filings/0001493152-26-021536.md) | [(6,926) d](/filings/0001493152-26-036200.md) |
| Capital expenditure | $k | [30.3 d](/filings/0001493152-24-044032.md) | [109 d](/filings/0001493152-25-009790.md) | [176](/filings/0001641172-25-008864.md) | [642 d](/filings/0001641172-25-022272.md) | [448 d](/filings/0001493152-25-023906.md) | [198 d](/filings/0001493152-26-009549.md) | [118](/filings/0001493152-26-021536.md) | [777 d](/filings/0001493152-26-036200.md) | [821 d](/filings/0001493152-25-023906.md) | [155 d](/filings/0001493152-26-009549.md) | [105](/filings/0001493152-26-021536.md) | [67.8 d](/filings/0001493152-26-036200.md) |
| Dividends paid | $k | [777 d](/filings/0001493152-24-044032.md) | [777 d](/filings/0001493152-25-009790.md) | [777](/filings/0001641172-25-008864.md) | [777 d](/filings/0001641172-25-022272.md) | [777 d](/filings/0001493152-25-023906.md) | [777 d](/filings/0001493152-26-009549.md) | [777](/filings/0001493152-26-021536.md) | [777 d](/filings/0001493152-26-036200.md) | [777 d](/filings/0001493152-25-023906.md) | [777 d](/filings/0001493152-26-009549.md) | [777](/filings/0001493152-26-021536.md) | [777 d](/filings/0001493152-26-036200.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [270](/filings/0001493152-25-023906.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.9](/filings/0001493152-23-039923.md) | [31.7](/filings/0001493152-24-018250.md) | [32.6](/filings/0001493152-24-030564.md) | [34.5](/filings/0001493152-24-044032.md) | [39.2](/filings/0001641172-25-008864.md) | [41.3](/filings/0001641172-25-022272.md) | [42.0](/filings/0001493152-25-023906.md) | [43.1](/filings/0001493152-26-021536.md) | [44.4](/filings/0001493152-26-036200.md) | [46.2](/filings/0001493152-25-023906.md) | [47.3](/filings/0001493152-26-021536.md) | [47.8](/filings/0001493152-26-036200.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,200,837 at 2026-08-04, from the cover of the [10-Q filed 2026-08-05](/filings/0001493152-26-036200.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.